Exelixis Stock Working Capital

EXEL Stock

USD 36.46 0.53 1.48%

Exelixis fundamentals help investors to digest information that contributes to Exelixis' financial success or failures. It also enables traders to predict the movement of Exelixis Stock. The fundamental analysis module provides a way to measure Exelixis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exelixis stock.

	Last Reported	Projected for Next Year
Net Working Capital	923.7 M	1.1 B
Change In Working Capital	-14 M	-13.3 M

Net Working Capital is expected to rise to about 1.1 B this year, although the value of Change In Working Capital is projected to rise to (13.3 M).

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Exelixis Company Working Capital Analysis

Exelixis' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Exelixis Working Capital

923.68 M

Most of Exelixis' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exelixis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Exelixis Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Exelixis is extremely important. It helps to project a fair market value of Exelixis Stock properly, considering its historical fundamentals such as Working Capital. Since Exelixis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Exelixis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Exelixis' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Retained Earnings	Net Debt	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Good Will	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.72	-0.68	0.95	0.94	0.96	0.34	0.96	-0.34	-0.33	-0.55	-0.26	-0.43	0.94	-0.09	0.99	-0.69	0.83	0.78	0.93	-0.59	0.97	0.91	0.78
Total Stockholder Equity	0.99		0.78	-0.76	0.92	0.95	0.97	0.2	0.97	-0.39	-0.26	-0.61	-0.25	-0.39	0.94	-0.03	0.99	-0.73	0.81	0.79	0.9	-0.64	0.99	0.94	0.75
Retained Earnings	0.72	0.78		-0.61	0.67	0.69	0.69	-0.18	0.68	-0.6	0.34	-0.58	-0.53	-0.48	0.78	-0.05	0.78	-0.53	0.39	0.44	0.73	-0.61	0.78	0.75	0.59
Net Debt	-0.68	-0.76	-0.61		-0.55	-0.82	-0.76	0.15	-0.82	0.4	0.07	0.77	-0.04	-0.01	-0.74	-0.1	-0.67	0.82	-0.67	-0.77	-0.46	0.64	-0.76	-0.83	-0.46
Accounts Payable	0.95	0.92	0.67	-0.55		0.89	0.89	0.43	0.88	-0.26	-0.25	-0.49	-0.39	-0.54	0.92	-0.3	0.94	-0.61	0.79	0.72	0.91	-0.51	0.9	0.84	0.8
Net Receivables	0.94	0.95	0.69	-0.82	0.89		0.91	0.21	0.95	-0.32	-0.28	-0.66	-0.25	-0.39	0.97	-0.12	0.94	-0.78	0.83	0.84	0.79	-0.62	0.93	0.92	0.72
Short Term Investments	0.96	0.97	0.69	-0.76	0.89	0.91		0.24	0.98	-0.39	-0.33	-0.6	-0.14	-0.29	0.88	-0.06	0.94	-0.74	0.82	0.8	0.83	-0.62	0.95	0.95	0.72
Total Liab	0.34	0.2	-0.18	0.15	0.43	0.21	0.24		0.25	0.22	-0.57	0.2	0.16	-0.02	0.24	-0.33	0.23	0.03	0.47	0.15	0.36	0.12	0.22	0.12	0.15
Total Current Assets	0.96	0.97	0.68	-0.82	0.88	0.95	0.98	0.25		-0.35	-0.34	-0.59	-0.09	-0.24	0.92	-0.09	0.92	-0.73	0.84	0.8	0.8	-0.6	0.96	0.97	0.72
Short Term Debt	-0.34	-0.39	-0.6	0.4	-0.26	-0.32	-0.39	0.22	-0.35		-0.16	0.43	0.16	0.12	-0.35	-0.07	-0.38	0.4	-0.06	-0.23	-0.33	0.88	-0.36	-0.35	-0.21
Common Stock	-0.33	-0.26	0.34	0.07	-0.25	-0.28	-0.33	-0.57	-0.34	-0.16		-0.19	-0.54	-0.23	-0.13	-0.08	-0.22	0.11	-0.44	-0.29	-0.21	0.05	-0.23	-0.22	-0.15
Long Term Debt	-0.55	-0.61	-0.58	0.77	-0.49	-0.66	-0.6	0.2	-0.59	0.43	-0.19		0.32	0.29	-0.59	-0.14	-0.6	0.95	-0.55	-0.84	-0.44	0.66	-0.59	-0.56	-0.38
Good Will	-0.26	-0.25	-0.53	-0.04	-0.39	-0.25	-0.14	0.16	-0.09	0.16	-0.54	0.32		0.94	-0.39	0.22	-0.38	0.17	0.03	-0.16	-0.41	0.17	-0.19	-0.11	-0.47
Intangible Assets	-0.43	-0.39	-0.48	-0.01	-0.54	-0.39	-0.29	-0.02	-0.24	0.12	-0.23	0.29	0.94		-0.5	0.23	-0.52	0.24	-0.13	-0.3	-0.55	0.22	-0.31	-0.22	-0.62
Property Plant Equipment	0.94	0.94	0.78	-0.74	0.92	0.97	0.88	0.24	0.92	-0.35	-0.13	-0.59	-0.39	-0.5		-0.19	0.94	-0.68	0.76	0.73	0.84	-0.59	0.93	0.91	0.77
Current Deferred Revenue	-0.09	-0.03	-0.05	-0.1	-0.3	-0.12	-0.06	-0.33	-0.09	-0.07	-0.08	-0.14	0.22	0.23	-0.19		-0.06	-0.16	-0.04	0.1	0.02	-0.06	-0.04	-0.11	-0.21
Net Tangible Assets	0.99	0.99	0.78	-0.67	0.94	0.94	0.94	0.23	0.92	-0.38	-0.22	-0.6	-0.38	-0.52	0.94	-0.06		-0.71	0.8	0.78	0.93	-0.62	0.96	0.89	0.76
Long Term Debt Total	-0.69	-0.73	-0.53	0.82	-0.61	-0.78	-0.74	0.03	-0.73	0.4	0.11	0.95	0.17	0.24	-0.68	-0.16	-0.71		-0.71	-0.94	-0.54	0.7	-0.7	-0.67	-0.46
Capital Surpluse	0.83	0.81	0.39	-0.67	0.79	0.83	0.82	0.47	0.84	-0.06	-0.44	-0.55	0.03	-0.13	0.76	-0.04	0.8	-0.71		0.85	0.69	-0.42	0.83	0.75	0.42
Deferred Long Term Liab	0.78	0.79	0.44	-0.77	0.72	0.84	0.8	0.15	0.8	-0.23	-0.29	-0.84	-0.16	-0.3	0.73	0.1	0.78	-0.94	0.85		0.63	-0.59	0.75	0.7	0.53
Long Term Investments	0.93	0.9	0.73	-0.46	0.91	0.79	0.83	0.36	0.8	-0.33	-0.21	-0.44	-0.41	-0.55	0.84	0.02	0.93	-0.54	0.69	0.63		-0.51	0.88	0.76	0.75
Short Long Term Debt	-0.59	-0.64	-0.61	0.64	-0.51	-0.62	-0.62	0.12	-0.6	0.88	0.05	0.66	0.17	0.22	-0.59	-0.06	-0.62	0.7	-0.42	-0.59	-0.51		-0.59	-0.57	-0.39
Net Invested Capital	0.97	0.99	0.78	-0.76	0.9	0.93	0.95	0.22	0.96	-0.36	-0.23	-0.59	-0.19	-0.31	0.93	-0.04	0.96	-0.7	0.83	0.75	0.88	-0.59		0.95	0.69
Net Working Capital	0.91	0.94	0.75	-0.83	0.84	0.92	0.95	0.12	0.97	-0.35	-0.22	-0.56	-0.11	-0.22	0.91	-0.11	0.89	-0.67	0.75	0.7	0.76	-0.57	0.95		0.74
Capital Stock	0.78	0.75	0.59	-0.46	0.8	0.72	0.72	0.15	0.72	-0.21	-0.15	-0.38	-0.47	-0.62	0.77	-0.21	0.76	-0.46	0.42	0.53	0.75	-0.39	0.69	0.74

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Exelixis

Working Capital Over Time

Exelixis Capital Surpluse

Capital Surpluse

2.13 Billion

At this time, Exelixis' Capital Surpluse is quite stable compared to the past year.

According to the company's disclosures, Exelixis has a Working Capital of 923.68 M. This is 117.0% higher than that of the Biotechnology sector and 71.49% higher than that of the Health Care industry. The working capital for all United States stocks is 37.51% higher than that of the company.

Exelixis Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exelixis' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exelixis could also be used in its relative valuation, which is a method of valuing Exelixis by comparing valuation metrics of similar companies.

Exelixis is currently under evaluation in working capital category among its peers.

Exelixis ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Exelixis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Exelixis' managers, analysts, and investors.

Environmental

Governance

Social

Exelixis Fundamentals

	Return On Equity	0.2
	Return On Asset	0.13
	Profit Margin	0.22 %
	Operating Margin	0.35 %
	Current Valuation	9.27 B
	Shares Outstanding	285.58 M
	Shares Owned By Insiders	1.60 %
	Shares Owned By Institutions	89.22 %
	Number Of Shares Shorted	7.9 M
	Price To Earning	48.17 X
	Price To Book	4.51 X
	Price To Sales	4.93 X
	Revenue	1.83 B
	Gross Profit	1.55 B
	EBITDA	196.6 M
	Net Income	207.76 M
	Cash And Equivalents	1.53 B
	Cash Per Share	4.77 X
	Total Debt	189.94 M
	Debt To Equity	0.07 %
	Current Ratio	6.08 X
	Book Value Per Share	7.96 X
	Cash Flow From Operations	333.32 M
	Short Ratio	2.76 X
	Earnings Per Share	1.55 X
	Price To Earnings To Growth	2.61 X
	Target Price	31.83
	Number Of Employees	1.31 K
	Beta	0.51
	Market Capitalization	10.26 B
	Total Asset	2.94 B
	Retained Earnings	(173.35 M)
	Working Capital	923.68 M
	Current Asset	178.66 M
	Current Liabilities	52.25 M
	Net Asset	2.94 B

About Exelixis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Exelixis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exelixis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exelixis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:

How To Invest In Exelixis

Details

Is Exelixis Stock a good investment?

Details

What is Exelixis' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Exelixis Piotroski F Score and Exelixis Altman Z Score analysis.

For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

121.699

Earnings Share

1.55

Revenue Per Share

7.032

Quarterly Revenue Growth

0.143

Return On Assets

0.1281

The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Exelixis Stock Working Capital

Exelixis Company Working Capital Analysis

Working Capital

Current Assets

-

Current Liabilities

Current Exelixis Working Capital

Exelixis Working Capital Driver Correlations

Exelixis Capital Surpluse

Capital Surpluse

2.13 Billion

Exelixis Working Capital Peer Comparison

Exelixis ESG Sustainability

Exelixis Fundamentals

About Exelixis Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY